A study testing whether a new weekly shot from Lilly, tirzepatide, can help with weight.
What this means for you
- Who can join
- Children and teens 12 to 17, have obesity.
- What you take
- tirzepatide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 6.5 years; your own time in it is usually shorter.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Obesity. Also studied in: Weight Gain.
Full scientific study title: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2).
Who can join
Children and teens 12 to 17, have obesity. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Have body mass index (BMI) equal to or above the 95th percentile for age and sex (on age and gender-specific growth chart for diagnosis of obesity) with at least 2 of the following predefined weight-related comorbidities: hypertension, prediabetes and hypertriglyceridemia.
- Have history of at least 1 self-reported unsuccessful dietary effort to lose weight.
- Are capable of giving signed informed consent by a legal representative or assent by a study participant (when applicable).
Key exclusion criteria
- Have undergone or plan to undergo a weight reduction procedure during the study, such as, but not limited to
- gastric bypass
- sleeve gastrectomy
- restrictive bariatric surgery, such as Lap-Band gastric banding, or
- any other procedure intended to result in weight reduction.
Where this study is enrolling
This trial has 15 sites across 9 states. Contact a site coordinator directly to start screening.
California2 sites
- Children's Hospital Los AngelesLos Angeles, California
- Sutter Valley Medical Foundation (SVMF) Pediatric EndocrinologySacramento, California
Delaware1 site
- Nemours Children's Health - DelawareWilmington, Delaware
Georgia1 site
- CenExel iResearch, LLCDecatur, Georgia404-537-1281
Idaho1 site
- Medical Research PartnersAmmon, Idaho
Illinois1 site
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, Illinois
Indiana1 site
- Indiana University Health University HospitalIndianapolis, Indiana
New York2 sites
- UBMD PediatricsBuffalo, New York
- SUNY Upstate Medical UniversitySyracuse, New York
Texas5 sites
- Driscoll Children's HospitalCorpus Christi, Texas
- Epic Medical Research - DeSotoDeSoto, Texas
- Valley Institute of Research - Fort WorthFort Worth, Texas
- Consano Clinical Research, LLCShavano Park, Texas
- Texas Valley Clinical ResearchWeslaco, Texas
Utah1 site
- Alliance for Multispecialty Research, LLCLayton, Utah
Timeline
Started enrolling: 2024-06-03. Expected completion: 2030-12. Last updated on ClinicalTrials.gov: 2026-05-19.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
